Probenecid for seizure clusters during antiseizure medication reduction in presurgical focal epilepsy monitoring

Phase 2, randomised, double-blind trial of bumetanide and Placebo-COD Research Private Ltd in Focal Onset Epilepsy (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Proportion of patients without seizure between 60 minutes and 12 hours after treatment administration. Planned start Jul 2026; status: authorised.